Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...